Step Pharma Revenue and Competitors
Estimated Revenue & Valuation
- Step Pharma's estimated annual revenue is currently $3.1M per year.
- Step Pharma's estimated revenue per employee is $155,000
Employee Data
- Step Pharma has 20 Employees.
- Step Pharma grew their employee count by 0% last year.
Step Pharma's People
Name | Title | Email/Phone |
---|
Step Pharma Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $2.8M | 18 | 50% | N/A | N/A |
What Is Step Pharma?
Step Pharma is developing a novel class of oral nucleotide synthesis inhibitors specifically targeting cytidine triphosphate synthase 1 (CTPS1) to induce selective modulation of T and B cell populations. The discovery of CTPS1 as a potential target for immunomodulation was based on studies of humans with a CTPS1 deficiency (Martin et al., Nature. 2014 Jun 12;510(7504):288-92) providing genetic evidence that CTPS1 inhibition could be used to treat lymphoproliferative cancers and auto-immune diseases. Cytidine nucleotide triphosphate (CTP) is a precursor required for DNA synthesis, a crucial step in cell division. De novo synthesis of CTP depends on two enzymes, the CTP synthases 1 and 2 (CTPS1 and CTPS2). CTPS2 is expressed in most tissues whereas CTPS1 expression is low in all tissues including resting T and B cells, but rapidly and strongly up-regulated specifically in T and B cells following activation. Importantly, CTPS1-deficient patients only exhibit specific immunodeficiencies without other clinical problems and CTPS2 is not able to complement for the lack of CTPS1 in T and B cells. CTPS1 therefore represents a therapeutic target for a new class of highly selective immunomodulatory and oncology drugs. The anti-proliferative activity of CTPS1 inhibition has been demonstrated in multiple cancer cell lines and the pharmacokinetic/pharmacodynamic relationship has been established using several animal models of disease. Step Pharma is now preparing to take it's lead compound, STP938, forward into IND/CTA enabling studies with the aim to enter clinical development in 2021 focused on relapsed/refractory T cell lymphoma patients.
keywords:N/AN/A
Total Funding
20
Number of Employees
$3.1M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Step Pharma News
Now, a panel of higher-ranking judges will review the case in the last step before a Supreme Court appeal. Purdue Pharma Seeks Bankruptcy To...
I am pleased to say that we have taken some steps forward, but we still have a long way to go. Related. 'Rigged' healthcare? Genentech survey...
During the annual meetings for three major vaccine players, access advocates are asking investors to step in.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $4.4M | 37 | N/A | N/A |
#2 | $15.8M | 102 | 3% | N/A |